Charles Schwab Investment Management Inc Candel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 113,772 shares of CADL stock, worth $624,608. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,772
Previous 83,880
35.64%
Holding current value
$624,608
Previous $473,000
21.56%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CADL
# of Institutions
82Shares Held
15.2MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.2 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.6 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$9.81 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$8.9 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$4.96 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $159M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...